[{"id":"7af5903c-ccb7-4332-9da0-a8ee14110cd6","acronym":"KANDOVA","url":"https://clinicaltrials.gov/study/NCT06087289","created_at":"2023-10-17T15:12:53.757Z","updated_at":"2024-07-02T16:35:33.334Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT06087289 - KANDOVA","lead_sponsor":"Kancera AB","biomarkers":" HRD • BRCA","pipe":" | ","alterations":" HRD","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • KAND567"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/20/2023","start_date":" 04/20/2023","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-10-17"}]